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Abstract
The functional mechanisms involved in angiogenesis and the potential role of endoglin (ENG), recently described as a new
marker for this process, have not been explored in Myelodysplastic Syndromes (MDS). In order to gain insight in MDS
angiogenesis a combined analysis in bone marrow (BM) of gene expression levels, angiogenesis-related soluble factors and
functional angiogenesis-related studies was carried out. Ninety-seven MDS patients and forty-two normal BM samples were
studied. The morphology of the capillary-like structures originated by two endothelial cells lines in the BM environment of
patients with refractory cytopenia with multilineage dysplasia (RCMD) was different from those of the remaining MDS. In
addition, the BM mononuclear cells from RCMD patients displayed over-expression of VEGF, HIF and FN1 while they showed
reduced expression of ENG in contrast to the normal ENG expression of the remaining low-risk MDS and the high expression
of ENG in high-risk MDS subtype. Moreover, higher soluble ENG and soluble FLT-1 levels in BM microenvironment were
observed in RCMD cases, which distinguished them from other individuals. Therefore, the present study suggests that the
patterns of angiogenesis are different between the MDS subtypes. The differences in angiogenesis observed in RCMD
patients could be related to ENG abnormalities.
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Introduction
Myelodysplastic Syndromes (MDS) are a heterogeneous group
of hematopoietic malignancies, characterized by ineffective
haematopoiesis, hypercellular bone marrow (BM), dysplasia of at
least one lineage and cytopenias in the peripheral blood [1]. These
disorders are classified according to WHO criteria, which take into
account types and number of cell dysplasias, percentage of blasts
and cytogenetic abnormalities [2,3]. Moreover, based on these
parameters, MDS can be divided into four prognostic categories:
low, intermediate-1, intermediate-2 and high risk [4]. MDS are
stem cell disorders, however, some studies have recently stressed
the possibility that the BM microenvironment may play a relevant
role in the pathogenesis of these diseases [5]. In addition,
abnormalities in signal transduction, transcription activity, cell-
cycle control, epigenetic, mitochondrial DNA and angiogenesis
have been related to MDS [6].
Angiogenesis is the process by which new blood vessels are
formed from pre-existing vessels and it has been associated with
growth, dissemination and metastasis of solid tumours [7]. In
hematological malignancies, angiogenesis develops in different
way than in solid tumours [8,9]. There are conflicting evidences
regarding angiogenesis in MDS; some studies have proposed that
BM microvascular density (MVD) increases with MDS progres-
sion [10], whereas others suggest an increased vascularity in the
early but not the latter stages of MDS [11]. Differences between
MDS subtypes could explain these conflicting results and hence
the importance of the discrimination between the different entities
of MDS.
Endoglin (ENG) is an integral membrane glycoprotein whose
properties have made it a reliable marker of tumour angiogenesis
and a prime target for anti-angiogenic therapy [12]. ENG serves as
co-receptor for members of the transforming growth factor beta
(TGF-b) superfamily of proteins [13] and a major evidence for the
pivotal role of ENG in angiogenesis is that mice lacking Eng
(Eng2/2) die from cardiovascular defects at mid gestation with
major defects in yolk sac vasculature [13,14]. ENG is mainly
expressed in proliferating vascular endothelium and its expression
increases during tumour angiogenesis and inflammation [12,13].
Elevated expression of ENG correlates with the proliferation of
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tumour endothelial cells [15] and also in hematopoietic tumours
such as multiple myeloma [16] and in hairy cell leukemia [17].
The mechanism involved in the ENG over-expression is probably
multifactorial, being hypoxia one of the most suitable candidates.
In fact, many of the pathophysiological settings where ENG is
upregulated involve hypoxic microenvironments, as is the case of
tumour angiogenesis [18]. Although ENG is a membrane protein,
low levels of soluble protein (sENG) can be found in extracellular
medium. The appearance of this soluble protein form is probably
due to proteolytic cleavage of isoform membrane as occurs with
betaglycan, which can be shed by metalloproteinase 1 [19]. sENG
interferes with TFG-b signalling causing endothelial dysfunction
[20]. It has been demonstrated that sENG inhibits the capilar tube
formation ‘‘in vitro’’ and increases vascular permeability [21].
Most of the studies of angiogenesis in MDS have been focused
on malignant haematopoietic cells but there is growing evidence
that BM-derived endothelial cells may contribute to tumour
angiogenesis [22,23]. In addition, clonal cells may have interac-
tions with these BM endothelial cells and the contact between
endothelial cells and normal or malignant haematopoietic cells is
mediated by soluble angiogenic factors of the BM microenviron-
ment [24,25]. Therefore the role of endothelial cells in the BM
malignant microenvironment and their possible relationship with
the malignant clone remains to be clarified by functional studies
and not only assessed by immunohistochemistry that so far has
been the most used method of analyzing angiogenic activity in
MDS [26].
In order to gain insight in the mechanisms involved in
angiogenesis in MDS a study of the cellular expression and the
BM microenvironment levels of sENG and other angiogenic
factors was carried out. The results showed marked differences in
the angiogenesis in the MDS subtypes, and could open new
approaches in the treatment in MDS patients.
Design and Methods
1. Patients Samples
A total of 97 MDS patients and 42 age-matched controls were
included in the study. Classification of MDS was performed
according to the World Health Organization (WHO) criteria [3].
Twenty-nine patients were diagnosed as refractory cytopenia with
multilineage dysplasia (RCMD) and forty-six had other low-risk
MDS excluding RCMD: nineteen of them had a refractory
anemia (RA), twenty-two had a refractory anemia with ring
sideroblasts (RARS) and five patients had a 5q- syndrome. The
remaining twenty-two patients had a refractory anemia with excess
of blasts (RAEB: high-risk MDS) (Table S1). The study was
approved by the local ethical committees ‘‘Comite´ E´tico de
Investigacio´n Clı´nica, Hospital Universitario de Salamanca’’.
Written informed consent was obtained from each patient before
they entered the study.
Mononuclear cells as well as the supernatant fluid were isolated
from BM of MDS patients and controls by density gradient
(Ficoll). Total RNA from cells was extracted by homogenization in
TRIZOL (Invitrogen, Carlsbad, CA, USA) following the protocol
supplied by manufactures, and treated with RQ1 RNAse-Free
DNase (Promega, Madison, USA) to eliminate genomic DNA
contamination, and finally purified with RNeasy Minikit (Qiagen,
Hilden, Germany). The RNA quantity and quality was deter-
mined by Agilent 2100 Bioanalyzer (Santa Clara, CA, USA). The
BM supernatant fluid was collected by centrifugation. The liquid
was withdrawn carefully to avoid disturbing the cells and collected
in a separate container at 280uC.
2. BMEC-1 Cell Culture
The immortalised cell line, BMEC-1 (Bone marrow endothelial
cells), kindly donated by Dr. F.J. Candal (Centers for Disease
Control and Prevention, Atlanta, Georgia) was used in our studies
[27]. This cell line was generated by transfecting an early passage
of primary BMEC with a vector (pSVT) encoding the large T
antigen of SV40. BMEC-1 express vWF/Factor VIII and
maintain a phenotype similar to that of primary cells, even at
high passage number.
Cells were maintained in culture at 37uC in a humidified
atmosphere of 95% air and 5% CO2 in Medium MCDB 131
(Invitrogen) supplemented with 15% foetal calf serum (FCS),
10 ng/ml endothelial grow factor (EGF) and 1 mg/ml hydrocor-
tisone.
3. HMVEC-L Cell Culture
Lung-derived normal human microvascular endothelial cells
(HMVEC-L) were purchased from Clonetics (Lonza Walkersville,
MD, USA) and maintained exactly as recommended by the
manufacturer. Cells were cultured with the EGM-2MV bullet kit
containing endothelial cell basal medium-2 (EBM-2) and the
following growth supplements: hEGF, hydrocortisone, GA-1000,
FBS, VEGF, hFGF-B, R3-IGI-1 and ascorbic acid. The experi-
ments described in this study were performed on cells between
three and four passages.
4. Cell Proliferation Assay
Subconfluent BMEC-1 were plated in 96-well plates to a density
of 5,000 cells per well. Twelve hours after plating, cells were serum
starved (5% FCS) and the BM supernatant fluid from MDS
patients or controls was added (1:10 dilution). After incubation
during 24 h, 48 h or 72 h, Thiazolyl Blue Tetrazolium Bromide
(MTT, Sigma, Illinois, USA) was added to each well and
incubated for 4 h. The formazan crystals formed from MTT by
the living cells were dissolved in the lysis buffer (10% sodium
dodecyl sulfate (SDS); 5% isopropanol; 0.1M HCl) for 12 h, and
the formazan purple solution was detected using a Sunrise plate
reader (Bio-Tek, Instruments, Winooski, USA) at 595 nm. All
experiments were performed in quadruplicate.
5. Endothelial Cell Tube Formation Assay
Endothelial cell tube formation was assessed as previously
described Jerkic et al [28]. In brief a total of 8,000 BMEC-1 per
well were plated on MatrigelH precoated plates (BD Biosciences,
New Jersey, USA) and cultured in medium MCDB 131 with 15%
FCS. Half an hour later, the BM supernatant fluid from MDS
patients or controls was added in the wells (1:10 diluted). After
seeding on MatrigelH, cells spread and aligned with each other to
develop hollow, tube-like structures. Endothelial tube formations
were observed each hour during seven hours of incubation and the
morphological changes were photographed at 5 h using a phase
contrast inverted Zeiss Microscope (Carl-Zeiss, Jena, Germany).
Each experiment was performed in duplicate. As a control in one
of each 5 wells just culture medium was added. The experiment
was performed in the same way with HMVEC-L. Likewise, a total
of 8,000 HMVEC-L per well were plated on MatrigelH precoated
plates. However, in this case, it was used its appropriate culture
medium as described above.
6. Real-Time PCR
The expression levels of endoglin (ENG), vascular endothelial
grow factor (VEGF), hypoxia-inducible factor 1-alpha (HIF1) and
fibronectin (FN1) genes were analyzed by Real-Time PCR. First-
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strand cDNA was generated from 1 mg of total RNA using poly-
dT as primers with the M-MLV reverse transcriptase (Promega).
Real-time PCR was performed in triplicate. Each 20 ml reaction
contained 300 ng of cDNA, 400 nM of each primer, and 16 iQ
SybrGreen Supermix (Bio-Rad, Hercules, CA, USA). Standard
curves were run for each transcript to ensure exponential
amplification and to rule out non-specific amplification. The
expression level of the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene was used to normalize differences in input cDNA.
The reactions were run on an iQ5 Real-time PCR detection
system (Bio-Rad, Hercules, CA, USA). The primers were designed
for specific sequences and checked by BLAST algorithm [29].
Primer sequences were as follows:
GAPDH- forward: 59-CAG GGC TGC TTT TAA CTC TGG
TAA-39.
GAPDH- reverse: 59-GGG TGG AAT CAT ATT GGA ACA
TGT A-39.
ENG- forward: 59-AGG TGC TTC TGG TCC TCA GT-39.
ENG- reverse: 59-CCA CTC AAG GAT CTG GGT CT-39.
VEGF- forward: 59-CGA AGT GGT GAA GTT CAT GG-39.
VEGF- reverse: 59-CAC AGG ATG GCT TGA AGA TG-39.
HIF1- forward: 59-GTC ACT TTG CCA GCT CAA AA-39.
HIF1- reverse: 59-ACC AAC AGG GTA GGC AGA AC-39.
FN1- forward: 59-TCA CAG CTT CTC CAA GCA TC-39.
FN1- reverse: 59-TGG CTG CAT ATG CTT TCC TA-39.
7. Enzyme-linked Immunosorbent Assay
In order to assess the concentration of proangiogenic soluble
factors, an enzyme-linked immunosorbent assay (ELISA) was
carried out in the BM supernatant fluid from patients and controls.
The levels of sENG, soluble fms-like tyrosine kinase 1 (sFLT-1)
and VEGF were assessed by using commercially available kits
from R&D Systems (R&D Systems, Minneapolis, USA). The
whole protocol was performed following the instructions given by
the manufacturer.
8. Statistical Analysis
The relationship between clinical or biological data and
genomic characteristics was analyzed using an independent sample
ANOVA test or Mann-Whitney test. All P-values reported were
two-sided and statistical significance was defined as P-value ,0.05.
Statistical evaluation was carried out using the SPSS 15.0
statistical software. The graphics of the study show the mean 6
standard error of the mean or the median of each group that was
used for the comparisons in each experiment between the different
entities of MDS and the range in each case.
Results
BM Microenvironment from MDS Patients Induces
Endothelial Proliferation
Endothelial proliferation is crucial in the process of angiogen-
esis. First, we studied the effect of BM supernatant fluid from MDS
patients and controls on BMEC-1 proliferation, during eight days.
Endothelial cells reached the peak of maximum proliferation at the
sixth day (Figure 1A) and the values at this day were chosen for
comparison between different subgroups.
At the sixth day, MDS BM supernatant fluid induced a
significantly higher proliferation rate in BMEC-1 than the control
BM supernatant fluid (p,0.005). Specifically, the proliferation was
2.4 times higher in MDS than controls (Figure 1A) and this
significant difference (p,0.05) was detected in all three MDS
subgroups analyzed (low-risk excluding RCMD, RCMD, high-
risk) while no statistical differences in the endothelial proliferation
were observed between the three groups of MDS themselves
(Figure 1B).
BM Microenvironment from MDS Patients Induces
Abnormal Tube Formation
Tube formation indicates the extent of angiogenesis and is
considered to be an important prognostic factor in this process. To
investigate the BM supernatant fluid effects on BMEC-1
(Figure 2A) and HMVEC-L (Figure 2B) tube generation, we used
a common method for gauging in vitro angiogenesis, the capillary-
like tube formation assay on MatrigelH. As a control, the
endothelial tube formation by BMEC-1 and HMVEC-L was
maintained in culture medium (Figure 2Ai and 2Bi, respectively).
The tubes seem to be completely formed after five hours of
incubation, and this time was used to compare the effect of
different MDS BM supernatant fluid.
When the endothelial cells lines were cultured with BM
supernatant fluid from the control, there was a well organized
tube formation. The endothelial tube appearance in cells treated
with BM supernatant from controls and cell maintained in culture
medium was similar (Figure 2A and B i–ii). By contrast, the tube
morphology was strikingly influenced by BM supernatant fluid
from MDS patients. Therefore, BM supernatant fluid from MDS
patients induces morphogenetic changes in the endothelial tube
formation (Figure 2A and B iii–viii). MDS-treated BMEC-1 and
HMVEC-L tented to assemble and form aggregates along the
tube-like structures, which was not observed in control cells
(Arrows in Figure 2). Incubation with different BM supernatant
fluid from MDS stimulated the capillary network aggregation of
endothelial cells, including increasing areas covered by the cells
and lengths of network compared to controls (Figure 2A and B iii–
viii). It should be noted that the tubes originated after the
incubation of BMEC-1 and HMVEC-L with the BM supernatant
fluid from RCMD patients almost completely disrupted the
capillary networks (Figure 2 A and B vii–viii).
Endoglin and Other Angiogenic Factors Expression
Differences in RCMD Patients with Respect to Other MDS
Patients
Clonal-derived hematopoietic myeloid progenitor cells may
facilitate the angiogenesis without directly participating in this
process by promoting the activation of normal BMEC. To better
understand the role of ENG in the angiogenesis of MDS patients,
a gene expression study was performed. RNA obtained from BM
mononuclear cells from MDS was used to analyze four angiogenic
factors: ENG, VEGF, HIF1 and FN1. Regarding ENG expression,
no differences were observed between all MDS patients as a single
group and the control group (Figure S1A). However, marked
differences in the ENG levels were observed in the separate analysis
of MDS groups. Thus a down-regulation of ENG expression was
patent in RCMD patients (p,0.05). By contrast, ENG expression
in high-risk MDS cases was higher than in controls (p,0.05). No
differences were found between the ENG levels of low-risk MDS
(excluding RCMD) and healthy controls (Figure 3A).
Overall the expression levels of VEGF, HIF1 and FN1 in MDS
were significantly higher (p,0.05) than in controls (Figure S1B–D).
Thus, the low-risk MDS groups (including RCMD) showed over-
expression of VEGF (Figure 3B), HIF and FN1 (Figure S2) with
respect to the control group (p,0.05). Moreover, patients with
RCMD showed the highest values in the expression of these three
genes with respect to the other low-risk MDS (Figure 3B and
Figure S2). By contrast, no differences in high-risk MDS patients
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regarding VEGF, HIF1 and FN1 expression with respect to the
control group were observed (Figure 3B and Figure S2).
Patients with RCMD Display High Concentrations of Anti-
angiogenic Soluble Factors in the BM Microenvironment
To assess the levels of angiogenic and anti-angiogenic factors
present in the BM supernatant fluid in different MDS groups,
ELISA assays were carried out in the BM supernatant fluid from
MDS patients and controls. Therefore, circulating levels of sENG
and sFLT-1 as well as VEGF were analyzed.
The Figure 4 summarizes the results: RCDM displayed higher
levels of sENG with respect to the controls (p,0.005), the
remaining low-risk MDS (p,0.05) and the high-risk MDS patients
(p= 0.05). Moreover, sFLT-1 concentrations in BM supernatants
were higher in RCMD with respect to the healthy cases
(p= 0.001), the remaining low-risk MDS and high-risk patients
(p,0.005) (Figure 4B). By contrast, the study lacked in detect
differences in the concentration of VEGF in the three MDS
groups analyzed (Figure 4C).
Discussion
Myelodysplastic syndromes (MDS) are clonal stem cell diseases
in which altered angiogenic mechanisms have been described. In
the present study, a combined analysis of gene expression,
angiogenesis-related soluble factors and functional angiogenesis-
related studies were carried out in bone marrow (BM) of patients
with MDS. The results demonstrated marked differences in
angiogenesis in the subtypes of MDS. Thus, the patients with
refractory cytopenia with multilineage dysplasia (RCMD) showed
an abnormal angiogenesis characterised by an increased level of
soluble endoglin (sENG).
The involvement of the microenvironment in MDS disorders
has been stressed. However, most of angiogenesis studies in MDS
have been focused in plasma from peripheral blood, while results
regarding the BM microenvironment analysis are scarce [8,30,31].
In the present report functional studies in the non-cellular portion
of BM were performed. A proliferation assay showed that MDS
BM supernatant fluid stimulated bone marrow endothelial cells
(BMEC-1) proliferation more than supernatant fluid from controls.
Our results support the aberrant angiogenesis in MDS previously
Figure 1. Effect of MDS BM microenvironment on BMEC-1 proliferation. (A) BMEC-1 proliferation curve. To analyze the effect of the BM
supernatant fluid from MDS patients and controls on BMEC-1 proliferation, the cell line was incubated with BM supernatant fluid. The cell number
was estimated by MTT at two, four or six days. The measurement of absorbance is indicative of the rate of cell proliferation and each value of each
patient is the mean of four independent experiments. Each point is the mean of these values 6 SEM. The graphics show the increase of proliferation
in MDS patients. ANOVA test was used to analyze the overall MDS results at sixth day. The proliferation was 2.4 times higher in MDS than controls
(p,0.005). (B) The box plot compares median levels of BMEC-1 proliferation at sixth day in the different subtypes of MDS. Whiskers represent the
range. Significant differences between RCMD and the control group (p,0.01), the other low-risk MDS and the control group (p,0.05) and high-risk
MDS patients and the controls (p,0.05) were observed by Mann-Whitney test. MDS: myelodysplastic syndrome; BM: bone marrow; BMEC-1: bone
marrow endothelial cells; MTT: Thiazolyl Blue Tetrazolium Bromide; SEM: standard error of the mean; RCMD: refractory cytopenia with multilineage
dysplasia. (Controls n = 8; MDS n = 14; Low-Risk MDS excluding RCMD n = 6; RCMD n = 4; High-Risk MDS n = 4).
doi:10.1371/journal.pone.0053624.g001
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analyzed by other techniques [26,32,33]. In addition, the
generation of new vessels in MDS is critical in the multistep
process of conversion from normal to dysplastic BM [5,33]. The
endothelial tube formation by BMEC-1 and HMVEC-L in
MatrigelH was performed in the presence of BM supernatant fluid
from MDS patients and differences in thickness, structure and
density of the formed tubes were observed. In addition, the
differences between the capillary-like structures originated by
BMEC-1 in RCDM and the remaining patient groups were
evident. RCMD cases showed less extensive capillary network and
reduced vessel formation (Figure 2vii–viii). BM angiogenesis in
MDS has been usually studied by measuring the microvascular
density by immunohistochemistry [8,26,31,34]. However, this is
the first time, to our knowledge, that the formation of
pseudocapillaries in MDS BM supernatant fluid by means of
functional techniques has been carried out. Thus, the present
studies demonstrated that MDS patients displayed an abnormal
angiogenesis characterized by a high endothelial proliferation and
aberrant pseudocapillary formation. Therefore the BM microen-
vironment plays an important role in this aberrant angiogenesis.
It has been demonstrated that leukemic cells may have intimate
interactions with bone marrow endothelial cells (BMEC) and can
elicit the sprouting of new blood vessels from pre-existing
capillaries by the active release of angiogenic factors [32,33,35].
Based on this consideration, we focused our attention on the
analysis of several molecules in BM mononuclear cells from MDS
that have been reported to be involved in the angiogenesis
processes and could be influencing on BMEC behavior. Thereby,
we demonstrated that vascular endothelial grow factor (VEGF),
hypoxia-inducible factor 1-alpha (HIF), and fibronectin (FN1)
expression were differentially over-expressed in low- risk MDS
patients, including RCMD cases. These findings are supported by
some studies where VEGF and other angiogenic factors were
significant increase in overall MDS group [34]. In addition, the
Figure 2. Effect of the MDS BM microenvironment on BMEC-1 and HMVEC-L tube formation. BMEC-1 (A) and HMVEC-L (B) were seeded
at a concentration of 8,000 cells per well of 96-well plate and incubated for 7 h at 37uC in 5% CO2. The endothelial tube formation was photographed
at 5 h using a phase contrast inverted microscope. Each experiment was performed in duplicate. The pictures show the appearance of endothelial
cell tubes on MatrigelH precoated plates in culture medium (i) and BM supernatant fluid from healthy control (ii), RA (iii), RARS (iv), 5q syndrome (v),
RAEB (high-risk MDS) (vi) and RCMD (vii-viii) patients at 1:10 dilution in culture medium. As the arrows show in the figure, the tube morphology was
strikingly influenced by BM supernatant fluid from MDS (iii-viii) with respect to the controls (ii). The tubes originated after the incubation of BMEC-1 or
HMVEC-L with the BM supernatant fluid from RCMD patients (vii-viii) were almost completely disrupted and formed closed capillary networks. MDS:
myelodysplastic syndrome; BM: bone marrow; BMEC-1: bone marrow endothelial cells; HMVEC-L: lung-derived normal human microvascular
endothelial cells; RA: refractory anemia; RARS: refractory anemia with ring sideroblast; RAEB refractory anemia with excess of blasts; RCMD: refractory
cytopenia with multilineage dysplasia. (Controls n = 13; RA n = 5; RARS n = 6; 5q syndrome n = 2; RAEB n = 4; RCMD n = 7).
doi:10.1371/journal.pone.0053624.g002
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over-expression of these molecules could explain the abnormal
proliferation and tube formation by endothelial cell lines in low-
risk MDS.
However, angiogenesis involves two stage of vascular develop-
ment: the differential growth and sprouting of endothelial tubes
and the remodeling the primary endothelial network into a mature
circulatory system. Endoglin gene (ENG) encodes an endothelial
transmembrane protein that is required for both processes [14,21].
As ENG staining represents a powerful marker to quantify tumor
angiogenesis [13] we have evaluated the expression of ENG in
MDS cells and we have demonstrated an over-expression in the
high-risk cases. ENG expression is elevated during alterations in
vascular structure and has been associated to many cancers,
including breast, ovary, prostate and cervical cancer [20]. As
cellular ENG levels regulate the formation of new blood vessels
[14], ENG antibodies have been successfully used to elicit anti-
angiogenic effects in tumor-associated endothelium mouse models
where ENG was highly expressed [36]. These advances will
provide new approaches for the development of new therapies for
high-risk MDS patients.
Interestingly, ENG expression was significantly lower in RCMD
patients than in cell from healthy controls. This event may
resemble other vascular diseases, such as the hereditary hemor-
rhagic telangiectasia type I (HHT). HHT patients have signifi-
cantly lower ENG levels and are characterized by arteriovenous
malformations and focal loss of capillaries [37]. In addition, it has
been reported that isolated murine Eng+/2 cells display impaired
capillary tube formation and significantly less vascular structures
compared to wild type mice [28]. Based on these findings, we
suggest that the under-expression of ENG in RCMD patients could
be associated with the decreased blood vessel formation in vitro
models of angiogenesis observed in the same group of patients.
Furthermore, the expression variations in the diverse angiogenic
factors could play different roles in the MDS subtypes suggesting
different mechanisms involved in the pathogenesis of these diseases
leading to a different angiogenesis in patients with RCMD with
respect to the other MDS patients.
The results of ENG gene expression led us to investigate their
presence in the extracellular medium as well as the levels of soluble
fms-like tyrosine kinase 1 (sFLT-1) (anti-angiogenic factor) and
VEGF (angiogenic factor). RCMD patients showed the highest
levels of sENG and sFLT-1 in BM supernatant fluid with respect
to both the other MDS and the control group (Figure 4). By
contrast, the VEGF levels were similar to the controls. A high
concentration of sENG has been also described in acute myeloid
leukemia and chronic myeloproliferative disorders [38] and in
patients with pathologies associated to vascular dysfunction [39].
Elevated circulating concentrations of sENG and sFLT-1 have
been showed in the maternal endothelial dysfunction called
preeclampsia. In fact, some authors suggest that sENG may act
in concert with sFLT-1 to induce severe preeclampsia [21,40]. In
addition, some studies have displayed that sFLT-1 binds to and
neutralizes the pro-angiogenic actions of VEGF and the contri-
butions of sENG and sFLT-1 to the pathogenesis of maternal
preeclampsia are, at least in part, related to their inhibition of
TGFb and VEGF, respectively [41]. This finding could explain
the mitigated VEGF secretion observed in RCMD patients in
relation to the expression gene in the same group of patients.
Based on our results, we suggest that the soluble form of ENG
antagonizes the membrane bound form in RCMD patients and
therefore potentiates the anti-angiogenic actions of sFLT-1, by
Figure 3. ENG and VEGF RNA expression in mononuclear BM cells of MDS subtypes. The box plot compares median of ENG and VEGF
expression levels in BM mononuclear cells between the different MDS groups and controls. The gene expression levels were analyzed by RT-PCR.
Each sample was performed in triplicate. Value of each patient is the mean of these three experiments. Mann-Whitney test was used to analyze the
results. The box plot compares the RNA expression in BM mononuclear cells of subtypes of MDS. Whiskers represent the range. A down-regulation of
ENG was showed in RCMD cases (p,0.05). By contrast, ENG expression in high-risk MDS patients was higher than in controls or in the other MDS
(p,0.05). No significant differences in low-risk MDS excluding RCMD patients in ENG expression with respect to the healthy controls were found (A).
The low-risk MDS groups showed over-expression of VEGF with respect to the control group (p,0.05). Moreover, patients with RCMD showed the
highest values in the expression of this gene with respect to the other low-risk MDS. No significant differences in high-risk MDS patients in VEGF
expression with respect to the healthy controls were found (B). ENG: endoglin; VEGF: vascular endothelial grow factor; BM: bone marrow; MDS:
myelodysplastic syndrome; RCMD: refractory cytopenia with multilineage dysplasia; RAEB: refractory anaemia with excess of blasts. (Controls n = 13;
Low-Risk MDS excluding RCMD n = 22; RCMD n = 12; High-Risk MDS n = 16).
doi:10.1371/journal.pone.0053624.g003
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disrupting the capacity to form capillary tubes of BMEC-1 and
HMVEC-L as we have previously showed in this group of patients.
Angiogenesis is a balanced process between pro and anti-
angiogenic factors. In MDS patients, our results suggest the
presence of an altered balance that could be involved in RCMD
patients. In fact, RCMD patients showed high expression levels of
pro-angiogenic factors such as VEGF, HIF, and FN1. In contrast,
this group of MDS had low ENG expression, high levels of sENG
and sFLT-1 in BM microenvironment, a decrease level of VEGF
with respect to the expression gene and the reduced vessel
formation by endothelial cell lines. Regarding the increased
BMEC-1 proliferation observed in RCMD there are conflicting
evidences: endothelial cell proliferation is key early event in
angiogenesis, but some studies have demonstrated that myeloid
malignancies with high levels of sENG are characterized by a high
cellular proliferation rate in BMEC and even, in myelopoietic
lineage what could explain the high proliferation in an anti-
angiogenic environment [28,38]. Therefore we suggest that the
RCMD display features that tip the balance of angiogenesis and
appear to be impairing this process.
Previous studies have demonstrated an abnormal angiogenesis
in MDS. However most of them have analyzed the differences
between the low-risk and high-risk patients while the RCDM
patients were not included as an independent group [26,34]. The
RCMD has been recently proposed by the WHO classification as
a specific MDS disorder [2] and the present study showed these
patients had a different pattern of angiogenesis. These results
provide new insights in the molecular mechanisms of RCMD
patients that could be ENG-related. Furthermore, recently, it has
been suggested that the inhibition of putative protease involved in
sENG shedding may be of therapeutic benefit in the treatment of
preeclampsia [20]. These observations could provide new
therapeutic approaches for this specific subtype of MDS.
Supporting Information
Figure S1 ENG, VEGF, HIF1 and FN1 RNA expression in
mononuclear MDS BM cells. The box plot compares median
of ENG, VEGF, HIF1 and FN1 expression levels in BM
mononuclear cells between MDS and controls. To analyze the
gene expression levels of the angiogenic factors we used RT-PCR.
Each value of each sample is the mean of three independent
experiments. The box plot shows the differences between the
samples expression distributions in control and MDS group.
Whiskers represent the range. Mann-Whitney test was applied in
all cases. No significant differences were found in ENG expression
between MDS patients and control group (A). Overall the
expression levels of VEGF, HIF1 and FN1 in MDS were
significantly higher (p,0.05) than levels of controls (B-D). ENG:
endoglin; VEGF: vascular endothelial grow factor; HIF1: hypoxia-
inducible factor 1-alpha; FN1: fibronectin; BM: bone marrow;
MDS: myelodysplastic syndrome. (Controls n = 13; MDS n = 50).
(TIF)
Figure S2 HIF1 and FN1 RNA expression in mononucle-
ar BM cells of MDS subtypes. The box plot compares median
of HIF1 and FN1 expression levels in BM mononuclear cells
between the different MDS groups and controls. The gene
expression levels were analyzed by RT-PCR. Each sample was
performed in triplicate. Each value of each patient is the mean of
these three experiments. Mann-Whitney test was used to analyze
the results. The box plot compares the RNA expression in BM
mononuclear cells of subtypes of MDS. Whiskers represent the
range. The low-risk MDS groups showed over-expression of HIF1
and FN1 with respect to the control group (p,0.05). Moreover,
patients with RCMD showed the highest values in the expression
of these two genes with respect to the other low-risk MDS. Overall
no significant differences in high-risk MDS patients in HIF1 and
FN1 expression with respect to the healthy controls were found.
HIF1: hypoxia-inducible factor 1-alpha; FN1: fibronectin; BM:
bone marrow; MDS: myelodysplastic syndrome; RCMD: refrac-
tory cytopenia with multilineage dysplasia; RAEB: refractory
anaemia with excess of blasts. (Controls n = 13; Low Risk MDS
excluding RCMD n = 22; RCMD n = 12; High Risk MDS n = 16).
(TIF)
Table S1 Clinical and biological characteristics of MDS
patients.
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